Sequential and Combination Therapies of 223RaCl2 and Prostate-Specific Membrane Antigen Radioligand Therapy
(Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - December 1, 2023 Category: Nuclear Medicine Authors: Jadvar, H. Tags: INVITED PERSPECTIVE Source Type: research
177Lu-Prostate-Specific Membrane Antigen Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer and Prior 223Ra (RALU Study)
Conclusion: In this real-world setting, 223Ra followed by 177Lu-PSMA therapy in heavily pretreated patients with mCRPC was clinically feasible, with no indication of impairment of 177Lu-PSMA safety or effectiveness. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - December 1, 2023 Category: Nuclear Medicine Authors: Rahbar, K., Essler, M., Eiber, M., la Fougere, C., Prasad, V., Fendler, W. P., Rassek, P., Hasa, E., Dittmann, H., Bundschuh, R. A., Pabst, K. M., Kurtinecz, M., Schmall, A., Verholen, F., Sartor, O. Tags: Clinical Investigations Source Type: research
An Intrapatient Dosimetry Comparison of 177Lu-rhPSMA-10.1 and 177Lu-PSMA-I&T in Patients with Metastatic Castration-Resistant Prostate Cancer
Conclusion: Using 177Lu-rhPSMA-10.1 can significantly increase the tumor-absorbed dose and improve the TI compared with 177Lu-PSMA-I&T. An improved TI gives the flexibility to maximize tumor-absorbed doses up to a predefined renal dose limit or, in earlier disease, to reduce the radiation exposure to the kidney while still achieving an effective tumor dose. The function of at-risk organs such as the kidneys is being assessed in a prospective clinical trial. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - December 1, 2023 Category: Nuclear Medicine Authors: Rinscheid, A., Gable, A., Wienand, G., Pfob, C., Dierks, A., Kircher, M., Trepel, M., Weckermann, D., Lapa, C., Bundschuh, R. A. Tags: Clinical Investigations Source Type: research
68Ga-Labeled Fibroblast Activation Protein Inhibitor (68Ga-FAPI) PET for Pancreatic Adenocarcinoma: Data from the 68Ga-FAPI PET Observational Trial
Conclusion: We confirmed an association of 68Ga-FAPI PET SUVmax and histopathologic FAP expression in pancreatic cancer patients. Additionally, we found high detection rate and diagnostic accuracy, superior to those of 18F-FDG PET/CT. 68Ga-FAPI might become a powerful diagnostic tool for pancreatic cancer work-up. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - December 1, 2023 Category: Nuclear Medicine Authors: Kessler, L., Hirmas, N., Pabst, K. M., Hamacher, R., Ferdinandus, J., Schaarschmidt, B. M., Milosevic, A., Nader, M., Umutlu, L., Uhl, W., Reinacher-Schick, A., Lugnier, C., Witte, D., Niedergethmann, M., Herrmann, K., Fendler, W. P., Siveke, J. T. Tags: Clinical Investigations Source Type: research
Oncologic Staging with 68Ga-FAPI PET/CT Demonstrates a Lower Rate of Nonspecific Lymph Node Findings Than 18F-FDG PET/CT
Conclusion: 68Ga-FAPI PET/CT imaging demonstrated higher accuracy for true nodal involvement and therefore has the potential to replace 18F-FDG PET/CT imaging for cancer staging. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - December 1, 2023 Category: Nuclear Medicine Authors: Demmert, T. T., Pomykala, K. L., Lanzafame, H., Pabst, K. M., Lueckerath, K., Siveke, J., Umutlu, L., Hautzel, H., Hamacher, R., Herrmann, K., Fendler, W. P. Tags: Brief Communications Source Type: research
68Ga-Labeled Fibroblast Activation Protein Inhibitor PET/CT for the Early and Late Prediction of Pathologic Response to Neoadjuvant Chemotherapy in Breast Cancer Patients: A Prospective Study
Conclusion: Assessment of early changes in 68Ga-FAPI uptake during NAC by 68Ga-FAPI PET/CT can predict pCR and primary tumor concentric withdrawal in BC patients. 68Ga-FAPI PET/CT has great potential for the early and late prediction of the pathologic response to NAC in BC. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - December 1, 2023 Category: Nuclear Medicine Authors: Chen, L., Zheng, S., Chen, L., Xu, S., Wu, K., Kong, L., Xue, J., Chen, X., Miao, W., Zhu, Y. Tags: Clinical Investigations Source Type: research
Somatostatin Receptor Expression in Lung Neuroendocrine Tumors: An Analysis of DOTATATE PET Scans
Conclusion: Most metastatic lung NETs lack uniform SSTR expression and are thus suboptimal candidates for SSTR-targeted therapy. SSTR imaging in lung NETs should be evaluated carefully for uniformity of expression. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - December 1, 2023 Category: Nuclear Medicine Authors: Al-Toubah, T., Montilla-Soler, J., El-Haddad, G., Haider, M., Strosberg, J. Tags: Brief Communications Source Type: research
Chemokine Receptor PET/CT Provides Relevant Staging and Management Changes in Marginal Zone Lymphoma
Conclusion: Relative to CT, CXCR4-directed PET/CT led to AA changes for 27 of 100 patients. Chemokine receptor PET/CT may improve current diagnostic algorithms and influence management relative to CT alone, potentially obviating some biopsies. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - December 1, 2023 Category: Nuclear Medicine Authors: Duell, J., Buck, A. K., Hartrampf, P. E., Schlotelburg, W., Schneid, S., Weich, A., Dreher, N., Lapa, C., Kircher, M., Higuchi, T., Samnick, S., Serfling, S. E., Raderer, M., Rasche, L., Einsele, H., Topp, M. S., Kosmala, A., Werner, R. A. Tags: Clinical Investigations Source Type: research
First-in-Humans PET Imaging of KRASG12C Mutation Status in Non-Small Cell Lung and Colorectal Cancer Patients Using [18F]PFPMD
Conclusion: [18F]PFPMD is a safe and promising PET tracer for noninvasive screening of the KRASG12C mutation status in NSCLC and CRC patients. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - December 1, 2023 Category: Nuclear Medicine Authors: Li, X., Ye, J., Wang, J., Quan, Z., Li, G., Ma, W., Zhang, M., Yang, W., Wang, J., Ma, T., Kang, F., Wang, J. Tags: Clinical Investigations Source Type: research
ChatGPT: Can You Prepare My Patients for [18F]FDG PET/CT and Explain My Reports?
Conclusion: ChatGPT might adequately substitute for advice given to patients by nuclear medicine staff in the investigated settings. Improving the consistency of ChatGPT would further increase reliability. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - December 1, 2023 Category: Nuclear Medicine Authors: Rogasch, J. M. M., Metzger, G., Preisler, M., Galler, M., Thiele, F., Brenner, W., Feldhaus, F., Wetz, C., Amthauer, H., Furth, C., Schatka, I. Tags: Brief Communications Source Type: research
PSMA PET/CT for Response Assessment and Overall Survival Prediction in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Androgen Receptor Pathway Inhibitors
Conclusion: Our results demonstrate that PSMA PET/CT is a valuable imaging biomarker for response assessment and overall survival prediction when performed at 3 mo after ARPI treatment initiation in mCRPC patients. Both proposed PSMA response criteria (EAU/EANM and RECIP 1.0) seem to perform equally well. No PSMA flare was observed. Prospective validation of these findings is strongly needed. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - December 1, 2023 Category: Nuclear Medicine Authors: Shagera, Q. A., Karfis, I., Kristanto, P., Spyridon, S., Diamand, R., Santapau, A., Peltier, A., Roumeguere, T., Flamen, P., Artigas, C. Tags: Clinical Investigations Source Type: research
Molecular Markers Are Associated with Onset of Radioiodine Refractoriness in Patients with Papillary Thyroid Carcinoma
Conclusion: Our data show a significant association between the onset of RR-TC and mutations in telomerase reverse transcriptase promoter and tumor protein 53, indicating the need for a more extensive diagnostic workup in these patients. Certain genetic changes put patients with thyroid cancer at risk of developing cancer spread that does not respond to radioiodine therapy. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - December 1, 2023 Category: Nuclear Medicine Authors: Laschinsky, C., Theurer, S., Herold, T., Rawitzer, J., Weber, F., Herrmann, K., Brandenburg, T., Fuhrer-Sakel, D., Fendler, W. P., Weber, M. Tags: Brief Communications Source Type: research
Imaging Agents for PET of Inflammatory Bowel Disease: A Review
Inflammatory bowel disease (IBD), which encompasses ulcerative colitis and Crohn disease, is a chronic inflammatory disorder resulting from an aberrant immune response, though its exact cause is unknown. The current mainstay standard of care for the diagnosis and surveillance of IBD is endoscopy. However, this methodology is invasive and images only superficial tissue structures, revealing very little about the molecular drivers of inflammation. Accordingly, there is an unmet need for noninvasive imaging tools that provide reliable and quantitative visualization of intestinal inflammation with high spatial and molecular sp...
Source: Journal of Nuclear Medicine - December 1, 2023 Category: Nuclear Medicine Authors: Rezazadeh, F., Kilcline, A. P., Viola, N. T. Tags: Focus on Molecular Imaging Source Type: research
61Cu-Labeled Radiotracers: Alternative or Choice?
(Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - December 1, 2023 Category: Nuclear Medicine Authors: Fani, M., Nicolas, G. P. Tags: Hot Topics Source Type: research
Ethical Considerations for Artificial Intelligence in Medical Imaging: Data Collection, Development, and Evaluation
The development of artificial intelligence (AI) within nuclear imaging involves several ethically fraught components at different stages of the machine learning pipeline, including during data collection, model training and validation, and clinical use. Drawing on the traditional principles of medical and research ethics, and highlighting the need to ensure health justice, the AI task force of the Society of Nuclear Medicine and Molecular Imaging has identified 4 major ethical risks: privacy of data subjects, data quality and model efficacy, fairness toward marginalized populations, and transparency of clinical performance...
Source: Journal of Nuclear Medicine - December 1, 2023 Category: Nuclear Medicine Authors: Herington, J., McCradden, M. D., Creel, K., Boellaard, R., Jones, E. C., Jha, A. K., Rahmim, A., Scott, P. J. H., Sunderland, J. J., Wahl, R. L., Zuehlsdorff, S., Saboury, B. Tags: State of the Art Source Type: research
